Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …

Hepatocellular carcinoma (HCC) is one of the most common cancers, leading to the second
cancer-related death in the global. Although the treatment of HCC has greatly improved over …

Hepatocellular carcinoma (HCC) takes the predominant malignancy of hepatocytes with
bleak outcomes owing to high heterogeneity among patients. Personalized treatments …

Regorafenib is a sorafenib-derived chemotherapy drug belonging to the multikinase
inhibitor family. This agent effectively targets a wide range of tyrosine kinases involved in …

Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities,
reoccurrence after surgical resection, metastasis and heterogeneity. In addition to sorafenib …

Chimeric antigen receptor T cell (CAR-T) therapy to hematological malignancies has
demonstrated tremendous clinical outcomes. However, the therapeutic efficacy of CAR-T …

Cancers of the digestive tract are among the most prevalent types of cancer. These types of
cancers are often diagnosed at a late stage, which results in a poor prognosis. Currently …

Hepatocellular carcinoma (HCC) is frequently metastatic once diagnosed and less likely to
respond to curative surgery, emphasizing the need for the development of more sensitive …

Chemoresistance remains as a major hindrance in the treatment of hepatocellular
carcinoma (HCC). High mobility group box protein 1 (HMGB1) enhances autophagic flux …

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. This
malignancy is associated with poor prognosis and high mortality. Novel approaches for …